OR WAIT null SECS
Economical development and regulatory standards make the country a logical choice for trials.
Top Related Articles:
Due to the cost of developing biopharmaceutical products and problems with adequate subject recruitment for clinical trials in the United States and Western Europe, outsourcing clinical research in newly emerging regions is increasingly common. Although the most dominant emerging regions are primarily countries in Latin America, Central and Eastern Europe, and Asia, some countries in Africa are also becoming prominent locations.
Past concerns about inadequate infrastructure and socio-political and economic problems in many parts of Africa have impeded growth in clinical research in the past. However, changing requirements such as patient diversity and the need for greater subject numbers in clinical trials in parallel with improved clinical research environments in some African countries, such as South Africa, have resulted in notable growth in clinical research in the region.
Two factors distinguish South Africa from other countries in Africa: It's the most economically developed African country and it has established better regulatory standards for conducting clinical trials. However, several factors are responsible for its clinical research growth.
Firstly, South Africa's total population is nearly 48 million, which provides a large, diverse patient population. Secondly, the majority of subjects enrolled in clinical trials have not received any previous treatment for their disease, either because it is not available to them or they cannot afford it. These factors greatly facilitate subject recruitment and help meet diversity requirements. In addition, lower costs for clinical research and lower risk of litigation make South Africa attractive for foreign companies outsourcing clinical trials.
Although clinical research has been established in South Africa for a number of years, from 1997 to 1998 there was a 40% increase in total clinical trial activity due primarily to highly effective recruitment and retention rates.1 Recently, the most significant growth in clinical research occurred in disease areas prominent in South Africa, including HIV/AIDS, tuberculosis (TB), malaria, cancer, and diabetes. In addition, multisite trials in HIV, dermatology, hematology, asthma, chronic bronchitis, and pediatric and adult pain studies are becoming increasingly common.
The number of trials conducted in South Africa has been growing exponentially over the past couple of decades across a wide range of therapeutic areas. According to the Beare Pharmaceutical Industry Report on South Africa, in the year 2001 approximately 400 studies were conducted. This number has continued to grow due to highly successful recruitment rates among patient populations and an improved regulatory environment.
But despite South Africa's satisfactory clinical research environment, there are many vulnerable populations that live in great poverty and have little access to any medical care. Many of these individuals are poorly educated and tend to accept authority without question. This raises ethical issues when obtaining informed consent.
In addition, it is not surprising that the focus on clinical research has been on infectious diseases, particularly HIV/AIDS, TB, and malaria, as large numbers of the country's population are greatly affected by these diseases. However, because many are extremely vulnerable, such as the large number of HIV pediatric cases, improved regulatory measures to protect these individuals must be implemented.
Furthermore, language and cultural differences between ethnic/racial groups contribute additional barriers that must be taken into account. Taking greater measures to maintain international ethical standards particularly among vulnerable populations in South Africa will help pave the way for improved clinical research in other African countries.
South Africa Ethnic/Racial Groups
HIV epidemiology and clinical studies are especially prevalent in South Africa due to the growing epidemic of HIV/AIDS. At the end of 2007, 5.7 million inhabitants were living with HIV/AIDS,2 one of the worst AIDS epidemics in the world. As a result of these alarming statistics, in 2000 the South African government implemented an HIV Vaccine Action Campaign in an attempt to control the epidemic.
Currently, 60% of the world's HIV/AIDS infected people are in Africa, and 59% of all infected individuals are women.3 Because of the high incidence of mother to child transmission, as of September 2008, South Africa's Minister of Health announced a full-fledged commitment to the prevention of HIV transmission to children.
The first large-scale study to evaluate a candidate HIV vaccine on the African continent was recently announced by study collaborators in the United States and South Africa. The trial involves up to 3000 participants at five sites throughout the country and is expected to continue for four years.4 In previous Phase I and II trials, the vaccine was found to be safe and effective against HIV in more than half of the subjects tested. There is much hope that a safer and more effective vaccine will help control the exponential growth of this terrible epidemic.
After eight years of research, one South African developed HIV vaccine is to become the first African vaccine to undergo human clinical trials in the United States.5 Results could take between five to eight years, however, the accomplishment of an undeveloped nation such as South Africa to develop a candidate vaccine and undergo clinical trials is already a milestone. If successful, the impact on the HIV/AIDS epidemic in Africa could be very significant.
In 2006 the World Health Organization (WHO) ranked South Africa fifth among the world's 22 countries most burdened by TB. The incidence of TB has increased significantly in South Africa in parallel with the HIV/AIDS epidemic. According to the 2006 USAID Infectious Diseases Report on South Africa, up to 60% of adult TB patients are HIV-positive.6 Furthermore, TB is one of the principal causes of HIV-associated deaths among HIV patients.
However, since the emergence of the HIV epidemic, the Directly Observed Therapy Strategy known as DOTS has failed to contain the spread of TB, particularly in southern Africa. Furthermore, progress in developing a treatment against multidrug resistant strains has been relatively slow.
To conduct large scale Phase III TB vaccine trials and improve the infrastructure for research in South Africa, in 2007 Denmark's Medicon (in collaboration with Aeras Global TB Vaccine Foundation) trained 9000 South Africans in clinical research methods. This effort has facilitated clinical research in South Africa in all therapeutic areas.7
Of the several potential TB vaccines being developed for clinical trials, one candidate is currently undergoing Phase II trials in South Africa. This particular vaccine is the most advanced of a new generation of preventive TB vaccines, and is being tested in a Phase IIb proof-of-concept trial at the University of Cape Town. The vaccine will be given to children who have been immunized with the BCG vaccine at birth in order to improve the level of immune protection. This is the first proof-of-concept trial of a new preventive TB vaccine in infants after many years, and is part of an effort by the South African Tuberculosis Vaccine Initiative.8
Malaria is endemic in the low-altitude areas of the northern and eastern parts of South Africa, with seasonal transmission. The renewed increase in the incidence of malaria was a result of a ban by the West on the pesticide DTT in the early 1970s. Attempts to develop a vaccine that prevents infection have been unsuccessful, although there has been considerable progress over the past 25 years.
Approximately 90% of malaria-related deaths occur in sub-Saharan Africa, and the majority of malaria casualties are children under age five. Because malaria infection in Africa can be fatal, the incentive for developing a successful vaccine that provides long-lasting immunity is great.
The final phase of testing for "the world's most advanced malaria vaccine candidate" was recently initiated with five infants from Tanzania. Over the next few months, 16,000 children under the age of two will receive this malaria vaccine in several African countries, including South Africa. The successful completion of a Phase III trial would make the vaccine available possibly by 2012.9
A safe and effective children's vaccine for malaria prevention would greatly reduce malaria infection in South Africa, where according to the WHO most of the 1 million people killed by malaria are less than five years old.9
South Africa's relatively well-developed infrastructure and compliance with ICH-GCP guidelines are two factors that have contributed to the country's growth in clinical research relative to other countries in Africa. In 2000, a South African Good Clinical Practice (GCP) guideline was published by the South African Department of Health—a stricter version that strengthened the existing requirements was later published in 2006.
Despite the fact that approval processes are somewhat lengthy, currently averaging 12 to 14 weeks, review and approval by the Medicines Control Council (MCC)10 responsible for scientific, medical, and ethical issues relating to clinical trial applications in South Africa is fairly consistent. Other related agencies include the nonprofit organization South African Clinical Research Association (SACRA) and the local Industry/Regulatory Task Group (IRTG).
In 2001, the WHO's Regional Committee for Africa expressed concern that some health-related studies undertaken in the region were not subjected to any form of ethics review.11 There are several examples of ethically compromised clinical studies that have been conducted in South Africa in the past. One such study is a breast cancer study conducted by Werner Bezwoda, an oncology/hematology professor, on women at Baragwanath hospital in South Africa in 1995. A review revealed that no patient consent or ethics review were provided during the course of the clinical trial.11
Although some past studies have not met adequately with international standards, more recent legislative changes have been put into place. In addition to the requirement for ethical standards, there are additional requirements specific to conducting clinical trials in South Africa.
In 2005, the Department of Health released a national guideline outlining ethics in health research in South Africa requiring that Ethics Committees be "representative of the communities they serve and increasingly reflect the demographic profile of the population of South Africa." These guidelines, similar in principle to the International Conference on Harmonization for Good Clinical Practice guidelines (ICH GCP), specify in greater detail the requirements for diversity, demographic representation, and occupational identity specific to South Africa.12
The issue of ethical informed consent practices in South Africa is a controversial one. Limited education, poverty, inadequate protection of human rights, discrimination on the basis of health status, and limited access to preventive care and treatment options are all contributing factors.
Although there are significant improvements in the quality of clinical research, particularly involving ethical considerations, there are certain important aspects of the population that must be taken into account. These include political and socioeconomic factors, illiteracy, language barriers, and cultural differences among patient populations.
Political and socioeconomic factors. South Africa is a middle-income country with severe economic disparities. The majority of the population is categorized as socioeconomically low status and 50% of South Africans live below the poverty line.13 Almost two decades after the end of apartheid, vast racial inequalities still exist. Many South Africans continue to be underserved and disadvantaged because of their race and/or ethnicity, especially regarding health care.14 An awareness of these issues is vital to maintaining the standards appropriate for international research. Vigilance on the part of sponsors to ensure that past prejudices do not interfere with current studies is crucial.
Illiteracy. Recently, a new "speaking book" has been developed to help inform less-educated subjects of the benefits and risk factors involved in clinical trial participation. Some of the health-related topics covered include HIV infection, tuberculosis, and malaria. The advantage of these speaking books over conventional methods is that the books provide a verbal explanation accompanied by visuals rather than a written text.15 Considering the illiteracy rate among much of the clinical trial participants in South Africa, this new method will greatly improve subject understanding and help raise ethical standards. Although the reported literacy rate among adults in South Africa is 86%, this rate varies significantly among different ethnic/racial populations.13
Language barriers. There are 11 official languages, the most common are English and Africaans. Each of the 11 includes a number of regional dialects and variants. Nine of South Africa's official languages (all except Afrikaans and English) are Bantu languages. Bantu languages are a large branch of the Niger-Congo language family, which is represented throughout much of sub-Saharan Africa.
Because of British rule, English is the most common language of the government, business, and scientific communities. However, according to the 2002 Pan South African Language Board survey, only 22% of the population has an adequate understanding of spoken English, such as that used in political speeches. Furthermore, different regions in South Africa predominantly speak distinct languages, including Zulu, Sotho, and Africaans, depending on the dominant influences and ethnic groups.
Informed consent and other patient-related materials must be translated into the native language of the patient. In South Africa this is not a simple issue. Not only are there several official languages but there are not always well-established translation equivalents for standard clinical trial terminology. For example, one South African study concluded that language may create barriers to informed consent by prospective research participants when there are no local words for "randomization" or "placebo."16
Cultural differences. Informed consent concepts are interpreted differently in different parts of the world. In traditional, rural African communities for example, a form of "communitarianism" dominates.17 In this context, research is an altruistic endeavor that benefits society. Western ethical consent guidelines that emphasize the individual over the community may not apply in this type of environment.
To better address informed consent issues such as language and culture, the UNAIDS guidelines for HIV vaccine research recommends a process of consultation between community representatives, researchers, sponsors, and regulatory bodies to design a more effective strategy. One example of this approach that has already been executed is an advisory board in rural Hlabisa, South Africa.
The board consists of eight local people who serve as community liaisons to develop education materials, consult with and inform the community about new research projects, and provide advice to researchers about local needs for the ethical conduct of research.18 These individuals possess knowledge of the local culture and language(s), and are therefore well equipped to overcome potential barriers to clinical research, while ensuring that ethical standards are maintained during the process of informed consent.
In order to conduct responsible, successful clinical trials in South Africa, an understanding of the differences that exist among various populations, including socioeconomic factors, illiteracy, and language and cultural barriers, is crucial. An awareness of the limited education and medical access for many vulnerable populations is also important, especially in light of past studies that have ethically compromised these subject populations. Clinical research can be beneficial for both the sponsor and the participants only when ethical international standards are maintained.
Considering the large and diverse number of subjects that can be recruited for clinical trials in South Africa, it is understandably becoming an important research location. However, along with testing for safe and effective therapies, the opportunity to improve the health status of many patient populations is great. In addition, the large populations devastated by infectious diseases such as HIV, TB, and malaria may greatly benefit from recent drug developments and clinical research being conducted in South Africa.
Finally, according to many investigators, South Africa provides a better environment for trials than many other African nations. So it can serve both as a model for clinical research in Africa and to help improve preventive care.
Karen Politis Virk, MS, is director of biotech and pharmaceutical research at Language Connections, 2001 Beacon Street, Boston, MA 02135, email: email@example.com
1. H.M. Christley, "Conducting Clinical Trials in South Africa," South African Medical Journal, 88, 980-982 (1998).
2. UNAIDS 2008 Report on the Global AIDS Epidemic, http://data.unaids.org/pub/GlobalReport/2008/JC1511_GR08_ExecutiveSummary_en.pdf.
3. Global Campaign for Microbicides in Africa, 2006, a Positive Enabling Environment for Clinical Trials: The Case of South Africa, http://www.global-campaign.org/africa.htm.
4. Fred Hutchinson Cancer Research Center, "South Africa Starts Major HIV/AIDS Trial," News-Medical.Net, http://www.news-medical.net/?id=21812, February 11, 2007.
5. South Africa, The Good News, "SA Aids Vaccine Makes Medical History," http://www.sagoodnews.co.za/south_africa_in_the_world/sa_aids_vaccine_makes_medical_history.html, December 1, 2008.
6. USAID Infectious Diseases Report on South Africa, http://www.usaid.gov/our_work/global_health/id/tuberculosis/countries/africa/safrica_profile.html, October 20, 2006.
7. Ministry of Foreign Affairs of Denmark, http://www.investindk.com/visNyhed.asp?artikelID=14996, 2006.
8. Wellcome Trust, "Potential New TB Vaccine Enters Clinical Trial in South Africa," http://www.wellcome.ac.uk/News/2009/News/WTX054497.htm, April 23, 2009.
9. OneWorld US, "Malaria Vaccine Enters Final Tests," Inter Press Service, UN News Center, http://us.oneworld.net/article/364121-final-phase-malaria-vaccine, June 5, 2009.
10. Medicines Control Council, http://www.mccza.com/.
11. J.M. Kirigia, C. Wambebe, A. Baba-Moussa, "Status of National Research Bioethics Committees in the WHO African Region," BMC Medical Ethics, 6 (10) (2005),http://www.biomedcentral.com/1472-6939/6/10.
13. CIA, The World Fact Book—South Africa, https://www.cia.gov/library/publications/the-world-factbook/geos/sf.html, 2005.
14. Z. Kon and N. Lackan, "Ethnic Disparities in Access to Care Remain in Post-Apartheid South Africa," American Journal of Public Health, 98 (12) 2272-2277 (2008).
15. O. Kloiber and N. Duncan, "New Speaking Book on Clinical Trials Launched for Low Literacy Areas," Bizcommunity.com, http://medical.bizcommunity.com/Article/196/148/29464.html, October 18, 2008.
16. A. Karim and S. Salim, "Globalization, Ethics, and AIDS Vaccines," Science, 288 (5474) 2129 (2000), http://www.columbia.edu/itc/hs/pubhealth/p9408/readings/abdool_karim_2000.pdf.
17. R.B. Weiss, "An On-site Audit of the South African Trial of High Dose Chemotherapy for Metastatic Breast Cancer & Associated Publications," Journal of Clinical Oncology, 19, 2771-2777 (2001).
18. K. Moodley, "HIV Vaccine Trial Participation in South Africa: An Ethical Assessment," Journal of Medicine and Philosophy, 27, 197-215 (2002), http://jmp.oxfordjournals.org/cgi/content/short/27/2/197.
19. R. Shapiro and R. Stein, "Ethical and Legal Issues in AIDS Vaccine Trials," Human Rights, Fall 2004, 20-22.